The Medicines Company and Alnylam to initiate Phase III clinical programme of inclisiran

The Medicines Company and Alnylam Pharmaceuticals have entered an agreement with the US Food and Drug Administration (FDA) for the Phase III clinical programme of inclisiran to treat atherosclerotic cardiovascular disease (ASCVD) and familial hyperch …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news